medigraphic.com
ISSN 1810-2352 (Print)

2017, Number 4

<< Back Next >>

Rev Cub Med Int Emerg 2017; 16 (4)

Eosinophilia in Intensive Care Unit

Borre D, Dueñas CC, Almanza A, Ortiz RG, Arenas VAR, Ugarte US

Language: Spanish
References: 25
Page: 7-20
PDF size: 545.91 Kb.


ABSTRACT

Introduction: the existing evidence is not conclusive regarding the eosinophil count as a marker of ICU mortality. Nevertheless, the pathophysiological mechanisms that accompany the eosinophil activation lead to cardiopulmonary and thromboembolic complications that are potentially lethal.
Develop: a narrative review was made about eosinophilia in critical care patients. A systematic search was conducted in PubMed, Medline, Cochrane and RIMA, looking for articles both in English and Spanish, encompassing from January 1, 2000, to April 30, 2017, and using as keywords eosinophilia, critical care, pathophysiology and treatment. A critical review of the evidence was done following GRADE (Grades of Recommendation, Assessment, Development and Evaluation), determining the quality of the evidence and the grade of recommendation. A total of 25 papers were included. Two separate reviewers selected the publications according to their relevance and fit to the predetermined objectives, using their respective titles and summaries. When decisions were divergent, a consensus about the decision was searched for, and required to proceed. The reference list of the different studies was appropriately verified.
Conclusions: eosinophilia may serve as a supporting diagnostic parameter and it can become very useful in certain scenarios.


REFERENCES

  1. Escobar E.J, González J.E, Carrillo E. B, Guerra K.C, Mercado R. Eosinophil count at intensive care unit admissionwas not predictor of hospital mortality: results of a case control study. Journal of intensive Care. 2015; 27 (3): 1-6.

  2. Salido E, Cabañas P, Moraleda J.M. Síndromes hipereosinofílicos. Mastocitosis sistémicas. Medicine. 2012; 11 (21); 1298:1308.

  3. Chabot R, George T. Leukocytosis. International Journal of laboratory hematology Int. Jnl. Lab. Hem. 2014; 36: 279- 288.

  4. Klion A. Eosinophilia: a pragmatic approach to diagnosis and treatment. Hematology Am SocHematolEduc Program. 2015; 1: 92 - 97.

  5. Gotlib J, Tefferi A. Word Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management 2015. American Journal of Hematology. 2015; 99 (11): 1077 – 1089.

  6. Falchi L, Verstovek S. Eosinophilia hematologic disorders. Immunol Allergy Clin N Am 2015;35: 439- 452.

  7. Klim A. How I treat Hypereosinophilic syndromes. Blood 2015; 114 (18): 3736-3741 consultado el 15 Junio 21017, disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2773488/

  8. AcharyaKR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014; 289 (25): 17406-17415. Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4067173/

  9. Malikk A, Batra J. The antimicrobial activity of human eosinophil granule proteins: Involvement in host defense against pathogens. Critical Reviews in Microbiology 2012; 38: 168 -181.

  10. Connell E M; NurtamThB. Eosinophilia in infectious Diseases.Inmunol Allergy Clin N Am 2015; 35: 493: 522.

  11. Merino C, Martinez F, Cardemil F, Rodriguez J R. Absolute eosinophilis count as a marker of mortality in patients with severe sepsis and septic shock in an intensive. Journal of critical care. 2012; 27: 394 -399.

  12. Garnacho J, Huici M J, Gutiérrez A, López I, Márquez J.A, Macher H, Guerrero J M, Puppo A. Prognostic and diagnostic value of eosinopenia, C-reactive protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with suspicion of sepsis. Critical Care 2014; 18:R116.

  13. Mejia R, Nutman Th. Evaluation and Differential Diagnosis of Marked, persistent eosinophilia. Seminars in Hematology 2012; 49 (2): 149:159.

  14. Santhamoorthy P, Alexander K., Alshubaili A. Intravenous immunoglobulin in the treatment of drug rash eosinophilia and systemic symptoms caused by phenytoin. Annals of Indian Academy of Neurology ,15(4): 320–322.

  15. EL Omairi N., Abourazzak S., Chaouki S., Atmani S., Hida M. (2014). Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) induced by carbamazepine: a case report and literature review. The Pan African Medical Journal 2014; 18: 9.

  16. Singh J, Dinkar A, Atam V, Gupta K, Sahani, K. Drug reaction with eosinophilia and systemic symptoms syndrome associated with Nitrofurantoin. Journal of Research in Pharmacy Practice 2016; 5(1): 70–73.

  17. Lee J.-Y, Seol Y-J, Shin, D-W, Kim, D.-Y, Chun H.-W, Kim B.-Y, Jang A.-S. A Case of the Drug Reaction with Eosinophilia and Systemic Symptom (DRESS) Following Isoniazid Treatment. Tuberculosis and Respiratory Diseases 2015. 78(1): 27–30.

  18. Kaswala D. H. Drug Rash with Eosinophilia and Systemic Symptoms Syndrome Due to Anti-TB Medication. Journal of Family Medicine and Primary Care 2013, 2(1), 83–85.

  19. Fathi AT, Dec WG, Richter JM, Chen YB, Schwartzenberg SS, Holmavang GH, Hasserjian RP. A 27 YearOld Man with Diarrhea, Fatigue, and Eosinophilia. N Engl J Med 2014; 370: 861- 872.

  20. O Connell E, Nutman T. Eosinophilia in infectious diseases. Immunol Allergy Clin N Am 2015; 35: 493: 522.

  21. Coffin S, Benton S, Lenihan D, Naftilan A, Mendes L. Eosinophilic Myocaarditis – An unusual cause of left ventricular Hypertophy. Am J Med Sci 2015; 349 (4): 358- 362.

  22. Praveen A, Weller P. Eosinophils and Disease pathogenesis. Seminars in Hematology 2012; 49 (2): 113-119.

  23. Butterfield J.H, Weiler C.R. Treatment of Hypereosinophilic Syndromes – The First 100 year. SeminHematol 2012; 49 (2): 182-191.

  24. Valent Peter. Pathogenesis, classification, and therapy of eosinophilia and eosinophil disorder. Blood Reviews 2009; 23: 157-165.

  25. Rothenberg M, Klion A, Roufosse F, Kahn J E, Weller P, Simon H, at el. Treatment of Patients with the Hypereosinophilic Syndrome with Mepolizumab. N Engl J Med 2008; 358: 1215-1228.




2020     |     www.medigraphic.com